Mark Ragosa - Mar 16, 2022 Form 4 Insider Report for Kiniksa Pharmaceuticals, Ltd. (KNSA)

Role
Chief Financial Officer
Signature
/s/ Madelyn Zeylikman, Attorney-in-Fact for Mark Ragosa
Stock symbol
KNSA
Transactions as of
Mar 16, 2022
Transactions value $
-$3,069
Form type
4
Date filed
3/18/2022, 04:38 PM
Previous filing
Sep 7, 2021
Next filing
Mar 23, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KNSA Class A Common Share Options Exercise +872 +28.07% 3.98K Mar 16, 2022 Direct F1
transaction KNSA Class A Common Share Tax liability -$3.07K -303 -7.61% $10.13 3.68K Mar 16, 2022 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction KNSA Restricted Share Unit Options Exercise $0 -872 -25% $0.00 2.62K Mar 16, 2022 Class A Common Share 872 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer.
F2 The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, March 16, 2021.